Balaxi Q2 results: PAT drops sharply, USD 4M Dubai subsidiary investment

Revenue DeclineResults View source PDF Explain this filing

BALAXI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.7%Reaction day

₹41.98

prior close

₹39.96

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.3%-4.5% vs market

On the reaction day the stock moved 4.5 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.1

15m

+0.1

30m

+0.1

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

-4.7-0.3-4.5

Next day

-9.5+0.7-10.1

-7.1+0.6-7.7

-11.9+0.5-12.3

-14.5+1.1-15.6

-14.2+0.3-14.5

-14.2-0.2-14.0

15d

-14.8-2.2-12.6

-20.7-4.9-15.7

-40.4-7.5-33.0

-47.6-4.8-42.8

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Standalone Q2 revenue Rs 1,471 lakh vs Rs 1,651 lakh YoY, PAT Rs 19.49 lakh vs Rs 326.36 lakh. Consolidated Q2 revenue Rs 5,776 lakh vs Rs 7,327 lakh, PAT Rs 20.9 lakh vs Rs 458.74 lakh. Board approved USD 4 million equity infusion in wholly owned subsidiary Balaxi Global FZCO Dubai for expansion. Formulation plant at Jadcherla: setup done, test license obtained, Paracetamol and Piroxicam batches under stability study, GMP audit prep underway.

Likely market impact

Sharp drop in quarterly profit despite subsidiary expansion push and formulation plant milestones.